Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectranetics to Present at the 31st Annual J.P. Morgan Healthcare Conference

Spectranetics to Present at the 31st Annual J.P. Morgan Healthcare Conference

COLORADO SPRINGS, Colo., Dec. 27, 2012 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that it will be presenting at the 31st Annual J.P. Morgan Healthcare Conference being held January 7 – 10, 2013 in San Francisco.

Scott Drake, Spectranetics' Chief Executive Office and Guy Childs, Chief Financial Officer, are scheduled to speak at 10:30 a.m. Pacific time on Thursday, January 10th. Interested parties can access a live audio webcast at www.spectranetics.com. An archived presentation will be available on the Web site for 30 days. Scott Drake and Guy Childs will also be hosting investor meetings throughout the conference.

About Spectranetics

Spectranetics develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are sold in more than 40 countries and are used to treat arterial blockages in the heart and legs, as well as the removal of pacemaker and defibrillator leads.

The Company's Vascular Intervention (VI) products include a range of peripheral and cardiac laser catheters for ablation of occluded arteries above and below the knee and within coronary arteries. The Company also markets aspiration and thrombectomy catheters for the removal of thrombus and support catheters to facilitate crossing of coronary and peripheral arterial blockages.

The Lead Management (LM) product line includes excimer laser sheaths and cardiac lead management accessories for the removal of pacemaker and defibrillator cardiac leads. 

For more information, visit www.spectranetics.com.

CONTACT: COMPANY CONTACT
         The Spectranetics Corporation
         Guy Childs, Chief Financial Officer
         (719) 633-8333
         
         INVESTOR CONTACTS
         Westwicke Partners
         Lynn Pieper or Nicole Hellendoorn
         (415) 202-5678
         lynn.pieper@westwicke.com